Latest PDL BioPharma Inc. Stories

INCLINE VILLAGE, Nev., May 2, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company will release its first quarter 2013 financial results for the period ended March 31, 2013, on Thursday, May 9, 2013, after market close. PDL's management will host a conference call and webcast that day at 4:30 p.m. Eastern Time to discuss the financial results. A slide presentation relating to the call will be available via the webcast link on the PDL...

INCLINE VILLAGE, Nev., April 30, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company has appointed Peter S. Garcia to the position of vice president, chief financial officer (CFO) and acting chief accounting officer, effective as of May 13, 2013. Mr. Garcia has spent the last 16 years in various CFO positions for biotechnology companies. He joins PDL from BioTime, Inc. (NYSE MKT: BTX) where he served as CFO since 2011. (Logo:...

INCLINE VILLAGE, Nev., April 22, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) and Avinger, Inc. announced today that they closed a structured financing and royalty transaction on April 18, 2013, in which PDL will provide Avinger with up to $40 million of financing. (Logo: http://photos.prnewswire.com/prnh/20110822/SF55808LOGO) Founded and led by the visionary cardiologist and medical device entrepreneur, Dr. John Simpson, Avinger is a designer of therapeutic...

INCLINE VILLAGE, Nev., March 12, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has paid the March 12, 2013, regular quarterly dividend payment of $0.15 per share to all stockholders owning shares of PDL as of March 5, 2013, the record date. (Logo: http://photos.prnewswire.com/prnh/20110822/SF55808LOGO) About PDL BioPharma PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation...

INCLINE VILLAGE, Nev., March 11, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced royalty revenue guidance for the first quarter ending March 31, 2013, of approximately $92 million, as compared with actual royalty revenue of $77 million for the first quarter of 2012, a 19 percent increase. (Logo: http://photos.prnewswire.com/prnh/20110822/SF55808LOGO ) The forecasted growth in royalty revenues is driven by increased fourth quarter 2012 sales for all...

INCLINE VILLAGE, Nev., March 6, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the company will hold its annual meeting of stockholders on Tuesday, May 21, 2013, at 10:00 a.m. Pacific Time for all stockholders of record on March 28, 2013. The meeting will take place at the Hyatt Regency Hotel in Incline Village, Nevada. (Logo: http://photos.prnewswire.com/prnh/20110822/SF55808LOGO) About PDL BioPharma PDL pioneered the humanization...

LONDON, March 6, 2013 /PRNewswire/ -- On Tuesday, the markets retained their bullish mode as indices created yet another life-time high. The markets showed across the board improvement, and the Healthcare sector saw Johnson & Johnson creating a new all time high. The Dow Jones ended its latest session at 14,253.77, up 0.89 percent while NASDAQ was up 1.32 percent to close at 3,224.13. Similarly, S&P closed on a positive note at 1,539.79, up 0.96 percent. Our research...

INCLINE VILLAGE, Nev., March 4, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the adjusted conversion rate for the: 2.875% Convertible Senior Notes due February 15, 2015 (February 2015 Notes) is 173.200 shares of common stock per $1,000 principal amount or approximately $5.77 per share, effective March 6, 2013; 3.75% Convertible Senior Notes due May 1, 2015 (May 2015 Notes) is 151.6248 shares of common stock per $1,000 principal amount or...

INCLINE VILLAGE, Nev., March 1, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today reported financial results for the fourth quarter and full year ended December 31, 2012. (Logo: http://photos.prnewswire.com/prnh/20110822/SF55808LOGO) Total revenues in 2012 were $374.5 million, compared to $362.0 million in 2011, with royalty revenues increasing seven percent over full year 2011. For the fourth quarter of 2012, total revenues were $86.0 million, compared to...

INCLINE VILLAGE, Nev., Feb. 25, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company will release its fourth quarter and full year 2012 financial results for the period ended December 31, 2012, on Friday, March 1, 2013, after market close. PDL's management will host a conference call and webcast that day at 4:30 p.m. Eastern Time to discuss the financial results. A slide presentation relating to the call will be available via the webcast link...